Liechtenstein

Reimbursed Care Access

Liechtenstein follows European/EEA medicinal-authorisation frameworks: esketamine (Spravato) is authorised at the EU/EEA level and therefore can be placed on the market for clinical use; all classic serotonergic and other psychedelic compounds listed (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain controlled substances with no authorised routine medical indication or routine reimbursement outside clinical research. National reimbursement and access for authorised medicines (including esketamine) are determined through Liechtenstein’s statutory health insurance and local pricing/coverage procedures; individual coverage/prior‑authorisation decisions are handled by the national health insurers.